(19)
(11) EP 4 739 396 A1

(12)

(43) Date of publication:
13.05.2026 Bulletin 2026/20

(21) Application number: 24748511.3

(22) Date of filing: 08.07.2024
(51) International Patent Classification (IPC): 
A61P 35/00(2006.01)
C07K 16/30(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 2317/24; C07K 2317/76; A61P 35/00; C07K 2317/92; C07K 16/2863; A61K 2239/57; A61K 47/6849; A61K 47/68037; A61K 47/68031; A61K 40/4201; A61K 40/4204; A61K 40/31; A61K 40/11
(86) International application number:
PCT/US2024/037091
(87) International publication number:
WO 2025/014896 (16.01.2025 Gazette 2025/03)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 07.07.2023 US 202363525493 P

(71) Applicant: The United States of America, as represented by The Secretary, Department of Health and Human Services
Bethesda, MD 20892-7788 (US)

(72) Inventors:
  • FITZGERALD, David J.
    Bethesda, Maryland 20892 (US)
  • ANTIGNANI, Antonella
    Bethesda, Maryland 20892 (US)
  • SARNOVSKY, Robert
    Bethesda, Maryland 20892 (US)

(74) Representative: Symbiosis IP Limited 
Unit 5C Sbarc l Spark Building Maindy Road
Cardiff CF24 4HQ
Cardiff CF24 4HQ (GB)

   


(54) HUMANIZED 40H3 ANTIBODY